Levobupivacaine Altan (Levobupivacaine)

Levobupivacaine works by binding to voltage‑gated sodium channels on nerve membranes, stabilizing them in an inactive state. This blocks sodium influx, preventing depolarization and halting the transmission of pain signals, resulting in a reversible loss of sensation in the targeted area.

The dose of Levobupivacaine Altan is determined by the prescribing clinician based on the specific procedure, patient characteristics, and route of administration. Healthcare professionals calculate the appropriate concentration and volume to achieve effective anesthesia while minimizing risk.

Safety data for Levobupivacaine in pregnancy and breastfeeding are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Levobupivacaine Altan, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Both are amide‑type local anesthetics, but Levobupivacaine is often preferred when a safer cardiac profile is desired.

Levobupivacaine Altan should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture and extreme temperatures to maintain stability and potency.

Levobupivacaine is administered by a qualified healthcare professional via injection. Depending on the clinical need, it can be delivered epidurally, infiltratively into tissues, intrathecally into the spinal canal, or as a peripheral nerve block using appropriate aseptic techniques.

The most serious risks include cardiac arrhythmias, severe hypotension, respiratory depression, seizures, and systemic toxicity leading to central nervous system effects. Prompt recognition and supportive management are essential if these adverse events occur.

Levobupivacaine should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, severe cardiac conduction disorders, uncontrolled epilepsy, or in situations where a safer alternative is available. Clinicians must assess each patient’s medical history before use.